Clinical Trials Logo

Filter by:
NCT ID: NCT05659472 Completed - Depression Clinical Trials

The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis in HIV Patients With Depression

Start date: December 12, 2020
Phase: N/A
Study type: Interventional

HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT). Main hypothesis: A combination of spiritual awareness-based cognitive therapy (MSBCT) plus hypnotic interventions can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression. Small hypothesis 1. There was a decrease in cortisol levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; 2. There was an increase in serotonin levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; 3. There was a decrease in depression degree scores after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; 4. There was a higher reduction in cortisol levels in the intervention group compared to the control group in HIV patients with depression; 5. There was a higher increase in serotonin levels in the intervention group compared to the control group in HIV patients with depression; 6. There was a higher reduction in scores degree of depression in the intervention group compared to the control group in HIV patients with depression; 7. Decreased cortisol levels and increased serotonin levels affect depression degree scores in HIV patients with depression; 8. MSBCT plus hypnosis combination intervention is a factor that can affect depression degree scores reduction in HIV patients with depression;

NCT ID: NCT05658549 Completed - COVID-19 Clinical Trials

Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Start date: May 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

NCT ID: NCT05657717 Completed - Clinical trials for Chronic Suppurative Otitis Media

Safety Profile of Applied 100% Manuka Honey in Tympanoplasty

Start date: July 13, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Throughout history, honey has been recognized for its healing properties. The use of honey for its medicinal properties dates back to 2200 BCE. The purpose of this clinical trial is to learn about the otological safety of 100% Medical grade Manuka Honey given to tympanoplasty patients The main question it aims to answer is: Can 100% Medical Grade Manuka Honey given at the time of Tympanoplasty otologically safe? Participants in the intervention group will receive a wound dressing of 100% medical grade Manuka honey after reconstructive surgery of the tympanic membrane. Researchers will compare the intervention group to the control group assess otological safety.

NCT ID: NCT05656937 Completed - Pediatric ALL Clinical Trials

Oblique Versus Transverse Orientation Approach for Internal Jugular Venous Cannulation in Pediatrics

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

this study aimed to compare oblique versus transverse orientation approach in jugular venous cannulation in term of cannulation success in pediatric heart surgery patients

NCT ID: NCT05648526 Completed - Clinical trials for Ketamine-Induced Neurotoxicity

Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The compound ACTH4-10Pro8-Gly9-Pro10 is a synthetic analog molecule of an adrenocorticotropic hormone (ACTH) short fragment. That is free from hormonal effects and has neuromodulatory effects. We investigate the neuroprotective effects of ACTH4-10Pro8-Gly9-Pro10 can lessen neurotoxicity against ketamine in neonatal rats by looking at BDNF expression in the cortex and hippocampus tissue as well as BDNF blood levels.

NCT ID: NCT05648123 Completed - Clinical trials for Post-COVID-19 Syndrome

Effectiveness of Supportive Psychotherapy Through Internet-Based Teleconsultation on Psychological and Somatic Symptoms, Neutrophil-Lymphocyte Ratio, and Heart Rate Variability in Post Covid-19 Syndrome Patients

Start date: December 21, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the effectiveness of supportive psychotherapy in post covid-19 syndrome patients. The main questions it aims to answer are: 1. What is the effect of supportive psychotherapy on psychological and somatic symptoms in post covid-19 syndrome patients? 2. What is the effect of supportive psychotherapy on the neutrophil lymphocyte ratio in post covid-19 syndrome patients? 3. What is the effect of supportive psychotherapy on heart rate variability in post covid-19 syndrome patients? Participants will be given supportive psychotherapy in the form of an online group for 3 times a week with a duration of psychotherapy ranging from 1 - 2 hours per session. Researchers will compare the supportive psychotherapy group to education group as control. The control group will be given education about Post Covid-19 syndrome in the form of an online group for 3 times a week with a duration of around 1 - 2 hours per session.

NCT ID: NCT05637229 Completed - Clinical trials for Hand, Foot and Mouth Disease

A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia

Start date: November 28, 2022
Phase:
Study type: Observational [Patient Registry]

This study is a sero-survey study of infants aged 6 months to 71 months in Bandung City and West Bandung District. As initial data to find out how many children have been exposed to human enterovirus type 71 (HEV-71) which causes Hand, foot, and mouth disease (HFMD).

NCT ID: NCT05621239 Completed - COVID-19 Clinical Trials

A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People

Start date: March 15, 2023
Phase:
Study type: Observational

The purpose of this study is to characterize descriptively the BNT162b2 vaccination safety experience among the Indonesian people. We will look at adverse events (AEs) reported in Indonesia Vaccine Safety Website for people 12 years of age and older. AEs are unwanted reactions associated with the use of the BNT162b2 vaccine. They may or may not be caused by this vaccine. The secondary data collection will be exclusively from the Indonesia Vaccine Safety Website as requested by BPOM. This study does not seek additional participants. We will look at reported AEs for BNT162b2 vaccine since it became available in Indonesia. Individual data will be de-identified first before use. This will help protect personal information. We will study the AEs associated with the BNT162b2 vaccine in several ways. These include the type of AEs and which body parts affected, among others. This will help us understand it the vaccine is safe in Indonesian people.

NCT ID: NCT05614505 Completed - Clinical trials for Severe Acute Malnutrition

Efficacy and Acceptability of RUTFs in Indonesia

Start date: July 15, 2021
Phase: N/A
Study type: Interventional

Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and successful treatment of children with SAM, by providing Ready to Use Therapeutic Food (RUTF) through out-patient treatment. Since 2019, UNICEF has been working intensively to facilitate the local production of RUTF. This present study aims to assess the acceptability and efficacy of three locally produced RUTFs compared to the standard peanut based RUTF. The study will be implemented in Bogor district. A total of 300 children with uncomplicated SAM, aged 6-59 months old, meeting the inclusion criteria will be included in the study. This study is designed as a randomized controlled trial. The children will be allocated to one of the five intervention (1 control, 4 experimental) arms. Each child will receive one type of RUTF product for eight consecutive weeks. The ration given to a child will be based on the need for an intake of ~ 170 kcal/kg BW/day. Data will be collected at baseline, at weekly intervals and at exit. The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the eight-week efficacy trial. Differences in weight and height gain will be analyzed using ANCOVA, controlling for age, gender, food intake, and morbidity. Repeated measurement statistics will be used to analyze differences in growth patterns over the eight-week intervention.

NCT ID: NCT05614362 Completed - Inflammation Clinical Trials

Channa Striatus Extract on Albumin and Hs-CRP ESRD

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

This study is a randomised, double blind, placebo-controlled study in patients with ESRD on HD or CAPD based RRTs at Moewardi General Hospital in Surakarta, Indonesia from January to March 2021. Subjects were randomized to either a Channa striata or a placebo group and were given a three times daily dosage of 500 mg of Channa striatus extract or 500 mg maltodextrin, respectively for 21 days. Serum albumin and hs-CRP were measured at the baseline, and at the end of the study